We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

52 hedge funds and large institutions have $16.9M invested in BRAINSTORM CELL THERAPUTC in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 24 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more call options, than puts

Call options by funds: $3.84M | Put options by funds: $3.62M

0.09% less ownership

Funds ownership: 1.03% → 0.94% (-0.09%)

9% less funds holding

Funds holding: 57 → 52 (-5)

21% less capital invested

Capital invested by funds: $21.4M → $16.9M (-$4.49M)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

67% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 24

Holders
52
Holders Change
-5
Holders Change %
-8.77%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
24
Closed
10
Calls
$3.84M
Puts
$3.62M
Net Calls
+$222K
Net Calls Change
+$419K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$819K
2
GCP
GSA Capital Partners
United Kingdom
+$392K
3
PVI
Pura Vida Investments
New York
+$375K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$137K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$68.8K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$886K
2
Millennium Management
Millennium Management
New York
-$776K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$363K
4
TEE
Tibra Equities Europe
United Kingdom
-$331K
5
First Trust Advisors
First Trust Advisors
Illinois
-$284K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
26
Aptus Capital Advisors
Alabama
$53K -$8.21K -156 -13%
Two Sigma Investments
27
Two Sigma Investments
New York
$52K -$113K -2,143 -67%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$52K – – –
Wells Fargo
29
Wells Fargo
California
$44K +$1.31K +25 +3%
RJFSA
30
Raymond James Financial Services Advisors
Florida
$42K -$842 -16 -2%
CG
31
CFO4Life Group
Texas
$40K – – –
Bank of America
32
Bank of America
North Carolina
$38K -$86.2K -1,639 -68%
Charles Schwab
33
Charles Schwab
California
$38K – – –
UBS Group
34
UBS Group
Switzerland
$37K -$10.5K -200 -21%
Osaic Holdings
35
Osaic Holdings
Arizona
$37K – – –
Two Sigma Advisers
36
Two Sigma Advisers
New York
$35K -$31.6K -600 -46%
OQS
37
Occudo Quantitative Strategies
Florida
$34K +$35.7K +678 New
HI
38
Harbour Investments
Wisconsin
$27K -$4.16K -79 -13%
Barclays
39
Barclays
United Kingdom
$14K -$13.1K -249 -47%
Bank Julius Baer & Co
40
Bank Julius Baer & Co
Switzerland
$14K -$158 -3 -1%
IFAM
41
Institutional & Family Asset Management
Colorado
$10K – – –
WT
42
Washington Trust
Rhode Island
$8K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$7K – – –
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$5K -$1.21K -23 -18%
RE
45
RBC Europe
United Kingdom
$2.31K – – –
Fidelity Investments
46
Fidelity Investments
Massachusetts
$2K +$2.31K +44 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$1.59K -$5K -95 -75%
First Manhattan
48
First Manhattan
New York
$1K – – –
Walleye Capital
49
Walleye Capital
New York
$35 +$37.3K +709 New
TEE
50
Tibra Equities Europe
United Kingdom
– -$331K -5,800 Closed
1
2
3

BCLI Hedge Fund Activity: Q3 2021 in Review

52 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2021, worth a combined $16.9M — down 21% from $21.4M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of BCLI and 5 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 8 added.

The largest buyer was Sabby Management, adding an estimated $819K. The largest seller was JP Morgan Chase, cutting an estimated $886K.

  • 52 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2021, down from 57 in Q2 2021.
  • Funds reported $16.9M of BRAINSTORM CELL THERAPUTC stock for Q3 2021, down 21% quarter-over-quarter.
  • 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2021 and 10 closed out, a net change of -5 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2021 was Sabby Management, an estimated $819K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q3 2021 was JP Morgan Chase, an estimated $886K sold.

Based on aggregated 13F filings for Q3 2021.